论文部分内容阅读
目的:探讨长效与常规α-干扰素(Interferonα,IFNα)治疗慢性病毒性乙型肝炎(Chr-onic viral hepatitis B,CVHB)的临床疗效。方法:回顾性分析2010年1月~2012年1月我院收治的97例CVHB患者,在常规黄芩苷治疗方案的基础上,对照组采用常规IFNα-1b治疗,观察组采用长效IFNα-2a治疗。观察并比较两组患者治疗前后肝功能及不良反应情况。结果:经过48周治疗,两组CVHB患者肝功能较治疗前均有显著改善;观察组患者ALT、AST、HA、LN及γ球蛋白(γ-G)均显著低于对照组,差异有统计学意义(P<0.05);治疗48周后,观察组患者HBe Ag、HBs Ag及HBV-DNA转阴率显著高于对照组,差异有统计学意义(P<0.05);在治疗期间,观察组腹胀及恶心、纳差、乏力等不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论:长效IFNα-2a治疗CVHB较常规IFNα-1b疗法更有效改善患者肝功能、提高乙型肝炎病毒转阴率,不良反应少,值得推广。
Objective: To investigate the clinical efficacy of long-acting and conventional interferon-α (IFNα) in the treatment of chronic viral hepatitis B (CVHB). Methods: A total of 97 patients with CVHB admitted to our hospital from January 2010 to January 2012 were retrospectively analyzed. On the basis of conventional baicalin regimen, the control group was treated with conventional IFNα-1b. The observation group was treated with long-term IFNα-2a treatment. Observed and compared the two groups of patients before and after treatment of liver function and adverse reactions. Results: After 48 weeks of treatment, the liver function of both CVHB patients was significantly improved compared with that before treatment; the ALT, AST, HA, LN and γ-G in the observation group were significantly lower than those in the control group (P <0.05). After 48 weeks treatment, the negative rate of HBeAg, HBsAg and HBV-DNA in the observation group was significantly higher than that in the control group (P <0.05). During the treatment period, Group abdominal distension and nausea, anorexia, fatigue and other adverse reactions was significantly lower than the control group, the difference was statistically significant (P <0.05). CONCLUSION: Long-term IFNα-2a treatment of CVHB is more effective than conventional IFNα-1b therapy in improving liver function and hepatitis B virus conversion rate with fewer adverse reactions and is worth promoting.